Defunct Company
Total Trials
2
As Lead Sponsor
As Collaborator
0
Total Enrollment
8
NCT02317549
Treatment of Septic Shock by Inhibiting Autodigestion and Preserving Gut Integrity With Enteric LB1148
Phase: Phase 2
Role: Lead Sponsor
Start: Apr 30, 2015
Completion: Mar 31, 2016
NCT04390217
LB1148 for Pulmonary Dysfunction Associated With COVID-19 Pneumonia
Start: Oct 31, 2021
Completion: Mar 31, 2022